The FDA Has Granted Priority Review To AstraZeneca's Capivasertib Plus Faslodex For Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced/Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted priority review to AstraZeneca's Capivasertib plus Faslodex for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced/metastatic breast cancer. The regulatory decision is expected in Q4 2023.
June 12, 2023 | 8:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Capivasertib plus Faslodex receives FDA priority review for advanced breast cancer treatment, with a decision expected in Q4 2023.
The FDA's priority review for AstraZeneca's Capivasertib plus Faslodex indicates a potentially faster approval process for the treatment. This could lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
AstraZeneca's Capivasertib plus Faslodex receives FDA priority review for advanced breast cancer treatment, with a decision expected in Q4 2023.
The FDA's priority review for AstraZeneca's Capivasertib plus Faslodex indicates a potentially faster approval process for the treatment. This could lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100